Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2014.
“In recent months, we have made substantial progress with our development program for AKB-6548 in renal anemia, most significantly, reporting positive top-line data from our Phase 2b study in non-dialysis patients with chronic kidney disease, or CKD.
Help employers find you! Check out all the jobs and post your resume.
“In recent months, we have made substantial progress with our development program for AKB-6548 in renal anemia, most significantly, reporting positive top-line data from our Phase 2b study in non-dialysis patients with chronic kidney disease, or CKD.
Help employers find you! Check out all the jobs and post your resume.
